Utility of peripheral blood flow cytometry in differentiating low grade versus high grade myelodysplastic syndromes (MDS) and in the evaluation of cytopenias

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 3, 2012, Pages 224-230

  Rashidi, Hooman H ^a   Xu, Xiangdong ^a   Wang, Huan You ^a   Shafi, Nelofar Q ^b   Rameshkumar, Karuna ^c   Messer, Karen ^d   Smith, Brian R ^b   Rose, Michal G ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Bone marrow; CD10; Flow cytometry; High grade MDS; Low grade MDS; Myelodysplastic syndromes; Peripheral blood

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE; TUMOR MARKER;

AGED; ARTICLE; BLOOD; CANCER GRADING; CASE CONTROL STUDY; CHRONIC MYELOMONOCYTIC LEUKEMIA; DIFFERENTIAL DIAGNOSIS; EVALUATION; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; IMMUNOLOGY; LEUKOPENIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PATHOLOGY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLOW CYTOMETRY; GRANULOCYTES; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKOPENIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM GRADING; NEPRILYSIN; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84861204904     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-1885.
2. Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009; 113: 6296-6303.
3. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D and Rick ME. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979-987.
4. van de Loosdrecht AA, Alhan C, Bene MC, Della Porta MG, Drager AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subira D, Valent P, van der Velden VH, VyasP, Westra AH, de Witte TM, Wells DA, Loken MRand Westers TM. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009; 94: 1124-1134.
5. Brunning RD, Porwit A, Orazi A, Baumann I, Germing U, Vardiman JW, Le Beau MM and Hellstrom-Lindberg E. Myelodysplastic syndromes/ neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press. 2008; 88-93.
6. Lorand-Metze I, Ribeiro E, Lima CS, Batista LS and Metze K. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 2007; 31: 147-155.
7. Kern W, Haferlach C, Schnittger S and Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010; 116: 4549-4563.
8. Hall J, Foucar K. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders. Int J Lab Hematol 2010; 32: 559-571.
9. Reis-Alves SC, Traina F, Saad ST, Metze K and Lorand-Metze I. The impact of several phenotypic features at diagnosis on survival of patients with myelodysplastic syndromes. Neoplasma 2010; 57: 530-536.
10. Harrington A, Olteanu H and Kroft S. The specificity of immunophenotypic alterations in blasts in nonacute myeloid disorders. Am J Clin Pathol 2010; 134: 749-761.
11. Huang M, Li J, Zhao G, Sui X, Zhao X and Xu H. Immunophenotype of myeloid granulocytes: a pilot study for distinguishing myelodysplastic syndrome and aplastic anemia by flow cytometry. Int J Lab Hematol 2009; 32: 275-281.
12. Xu F, Li X, Wu L, He Q, Zhang Z and Chang C. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSSbased immunophenotypes. Br J Haematol 2010; 149: 587-597.
13. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores-Montero J, Rasillo A, Sayagues JM, Sanchez ML, Barcena P, Hernandez-Rivas JM, Salvador C, Fernandez-Mosteirin N, Giralt M, Perdiguer L, Laranjeira P, Paiva A and Orfao A. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom 2010; 78: 154-168.
14. Stetler-Stevenson M, Yuan CM. Myelodysplastic syndromes: the role of flow cytometry in diagnosis and prognosis. Int J Lab Hematol 2009; 31: 479-483.
15. Ogata K, Della Porta MG, Malcovati L, Picone C, Yokose N, Matsuda A, Yamashita T, Tamura H, Tsukada J and Dan K. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 2009; 94: 1066-1074.
16. Truong F, Smith BR, Stachurski D, Cerny J, Medeiros LJ, Woda BA and Wang SA. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res 2009; 33: 1039-1046.
17. Stachurski D, Smith BR, Pozdnyakova O, Andersen M, Xiao Z, Raza A, Woda BA and Wang SA. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008; 32: 215-224.
18. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VH and Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111: 1067-1077.
19. Kussick SJ, Fromm JR, Rossini A, Li Y, Chang A, Norwood TH and Wood BL. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005; 124: 170-181.
20. Cherian S, Moore J, Bantly A, Vergilio JA, Klein P, Luger S and Bagg A. Flow-cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. Am J Hematol 2005; 79: 243-245.
21. Cherian S, Moore J, Bantly A, Vergilio JA, Klein P, Luger S and Bagg A. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom 2005; 64: 9-17.
22. Brunning RD, Bennett JM, Flandrin G, Matutes E and Head D. Myelodysplastic syndromes and acute myeloid leukemias In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours- Pathology and genetics of tumours of Hematopoietic and lymphoid tissues. IARC press 2001; pp: 61-106.
23. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G and Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
24. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp CLazzarino M, Aul C and Cazzola M. Timedependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
25. Chang CC, Cleveland RP. Decreased CD10-positive mature granulocytes in bone marrow from patients with myelodysplastic syndrome. Arch Pathol Lab Med 2000; 124: 1152-1156.
26. Connelly JC, Skidgel RA, Schulz WW, Johnson AR and Erdos EG. Neutral endopeptidase 24.11 in human neutrophils: cleavage of chemotactic peptide. Proc Natl Acad Sci USA 1985; 82: 8737-8741.
27. Terstappen LW, Safford M and Loken MR. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. Leukemia 1990; 4: 657-663.
28. Painter RG, Dukes R, Sullivan J, Carter R, Erdos EG and Johnson AR. Function of neutral endopeptidase on the cell membrane of human neutrophils. J Biol Chem 1988; 263: 9456-9461.
29. Knipp S, Strupp C, Gattermann N, Hildebrandt B, Schapira M, Giagounidis A, Aul C, Haas R and Germing U. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res 2008; 32: 33-37.
30. Cesana C, Klersy C, Brando B, Nosari A, Scarpati B, Scampini L, Molteni A, Nador G, Santoleri L, Formenti M, Valentini M, Mazzone A, Morra E and Cairoli R. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. Leuk Res 2008; 32: 1715-1723.
31. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG and Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104: 2263-2268.